

1. A compound of formula (I)



or a therapeutically acceptable salt or prodrug thereof, wherein


A is selected from the group consisting of




wherein the dotted line is either absent or is a single bond;

B is selected from the group consisting of hydrogen, alkyl, aryl, arylalkyl, heterocycle and heterocyclealkyl;

D is selected from the group consisting of




wherein Z is selected from the group consisting of alkoxy, alkyl, amino, cyano, nitro, CO_2P_1 , SO_3H , $\text{PO}(\text{OH})_2$, $\text{CH}_2\text{PO}(\text{OH})_2$, $\text{CHFPO}(\text{OH})_2$, $\text{CF}_2(\text{PO}(\text{OH})_2)_2$, $\text{C}(\text{=NH})\text{NH}_2$, and the following 5-membered heterocycles:



wherein P_1 and P_2 are independently selected from the group consisting of hydrogen, alkyl, alkenyl, arylalkyl, cycloalkyl and (cycloalkyl)alkyl;

R_1 , R_2 , R_3 , R_4 and R_5 are independently selected from the group consisting of hydrogen, alkoxy, alkyl, aryl, arylalkyl, cyano, halo, haloalkoxy, haloalkyl, heterocycle, heterocyclealkyl, hydroxy, hydroxyalkyl, nitro, NR_AR_B , $\text{NR}_A\text{R}_B\text{C}(\text{O})$, $\text{NR}_A\text{R}_B\text{C}(\text{O})$ alkyl and $\text{NR}_A\text{R}_B\text{C}(\text{O})$ alkenyl, wherein R_A and R_B are independently selected from the group consisting of hydrogen, alkyl, alkoxy, carbonyl, alkylsulfonyl, aryl, arylalkyl, carbonyl, arylcarbonyl, arylsulfonyl and $(\text{R}_C\text{R}_D)\text{N}$ carbonyl wherein R_C and R_D are independently selected from the group consisting of hydrogen, alkyl, aryl, and arylalkyl, or R_A and R_B taken together with the nitrogen to which they are attached form a ring selected from the group consisting of pyrrolidine, piperidine, morpholine, homopiperidine and piperazine;

L is selected from the group consisting of



$-(CH_2)_mX_1(CH_2)_nCH(R_8)C(R_{9A})(R_{9B})X_2(CH_2)_pE(CH_2)_qX_3-$, wherein each group is drawn with the left end attached to A and the right end attached to B;

m, n, p and q are independently between 0-4;

R_8 is selected from the group consisting of hydrogen, hydroxy, $NR_{9A}R_{9B}$ and $(NR_{9A}R_{9B})alkyl$;

R_{9A} and R_{9B} are independently selected from the group consisting of hydrogen, alkyl, hydroxyalkyl and $R_E R_F Nalkyl$, wherein R_E and R_F are independently selected from the group consisting of hydrogen, alkyl, alkoxyacetyl and alkanoyl, or R_{9A} and R_{9B} taken together are oxo;

R_{10} is selected from the group consisting of hydrogen, alkyl, alkanoyl and alkoxyacetyl;


R_{11} is independently selected from the group consisting of hydrogen, alkyl, alkenyl, arylalkyl, cycloalkyl, and (cycloalkyl)alkyl;

E is selected from the group consisting of aryl and cycloalkyl;

X_1 , X_2 , X_3 , and X_4 are independently absent or are independently selected from the group consisting of NR_G , O, S, $S(O)$ and $S(O)_2$, wherein R_G is selected from the group consisting of hydrogen, alkyl, alkanoyl and alkoxyacetyl; and


W_1 , W_2 , W_3 and W_4 are independently selected from the group consisting of CH , CH_2 , N, NH and O.

2. The compound according to claim 1 of formula (II)



or a therapeutically acceptable salt or prodrug thereof wherein A, B, L, P_1 , P_2 , R_1 , R_2 , and R_3 are defined in Claim 1.


3. The compound according to claim 2, wherein A is selected from the group consisting of



R_1, R_2, R_3, R_4 and R_5 are independently selected from the group consisting of hydrogen, alkoxy, alkyl, cyano, halo, haloalkoxy, haloalkyl, heterocycle, hydroxy, hydroxyalkyl, nitro, $NR_A R_B$, $NR_A R_B C(O)$, $NR_A R_B C(O)alkyl$ and $NR_A R_B C(O)alkenyl$; R_{10} is selected from the group consisting of hydrogen and alkyl; and R_{11} is independently selected from the group consisting of hydrogen, alkyl and arylalkyl.


4. The compound according to claim 2, wherein

L is




5. The compound according to claim 2, wherein

L is




6. The compound according to claim 2, wherein

L is




7. The compound according to claim 2, wherein

L is




R_{9A} and R_{9B} together are oxo; and
 X_2 is NR_C .

8. The compound according to claim 2, wherein
 L is




9. The compound according to claim 2, wherein
 L is




10. The compound according to claim 9, which is
 N -[5-({*N*-acetyl-4-[(carboxycarbonyl)(2-carboxyphenyl)amino]-3-ethylphenylalanyl} amino)pentanoyl]-L-tyrosine.

11. The compound according to claim 2, wherein
 L is



12. The compound according to claim 2, wherein

L is



R_8 is NR_AR_B ;

R_{9A} and R_{9B} together are oxo;

X_2 is NR_C ;

B is hydrogen; and

A is



13. The compound according to claim 12, which is

N-[5-({N-acetyl-4-[(carboxycarbonyl)(2-carboxyphenyl)amino]-3-ethylphenylalanyl}amino)pentanoyl]-L-norleucine.


14. The compound according to claim 2, wherein

L is



15. The compound according to claim 2, wherein


L is



R_8 is NR_AR_B .

16. The compound according to claim 2, wherein

L is




R_8 is NR_AR_B ; and

R_{9A} and R_{9B} together are oxo.

17. The compound according to claim 2, wherein

L is




R_8 is NR_AR_B ;

R_{9A} and R_{9B} together are oxo; and

X_2 is NR_C .

18. The compound according to claim 2, wherein

L is



R_8 is NR_AR_B ;


R_{9A} and R_{9B} together are oxo;

X_2 is NR_C ; and

B is hydrogen.

19. The compound according to claim 2, wherein

L is



R_8 is NR_AR_B ;

R_{9A} and R_{9B} together are oxo;


X_2 is NR_C ;

B is hydrogen; and

E is cycloalkyl.

20. The compound according to claim 2, wherein

L is



R_8 is NR_AR_B ;

R_{9A} and R_{9B} together are oxo;

X_2 is NR_C ;

B is hydrogen;

E is cycloalkyl; and

A is




21. The compound according to claim 20, which is

N-{[4-({[N-acetyl-4-[(carboxycarbonyl)(2-carboxyphenyl)amino]-3-(2-hydroxyethyl)phenyl]amino}methyl)cyclohexyl]carbonyl}-L-norleucine.

22. The compound according to claim 2, wherein

L is



R_8 is NR_AR_B ;

R_{9A} and R_{9B} together are oxo;


X_2 is NR_C ;

X_3 is S; and

B is alkyl.

23. The compound according to claim 2, wherein

L is



R_8 is NR_AR_B ;

R_{9A} and R_{9B} together are oxo;

X_2 is NR_C ;

X_3 is S;

B is alkyl; and

A is



24. The compound according to claim 23, selected from the group consisting of
N-{5-[(*N*-acetyl-4-[(carboxycarbonyl)(2-carboxyphenyl)amino]-3-ethylphenylalanyl)amino]pentanoyl}-L-methionine;

methyl *N*-{5-[(*N*-acetyl-4-[(carboxycarbonyl)(2-carboxyphenyl)amino]-3-ethylphenylalanyl)amino]pentanoyl}-L-methionine;

N-{5-[(*N*-acetyl-4-[(carboxycarbonyl)(2-carboxyphenyl)amino]-3-ethylphenylalanyl)amino]pentanoyl}-S-ethyl-L-homocysteine;


N-{5-[(*N*-acetyl-4-[(carboxycarbonyl)(2-carboxyphenyl)amino]-3-isopropylphenylalanyl)amino]pentanoyl}-L-methionine;

N-{5-[(*N*-acetyl-4-[(carboxycarbonyl)(2-carboxy-5-chlorophenyl)amino]-3-ethylphenylalanyl)amino]pentanoyl}-L-methionine; and

N-{5-[(*N*-acetyl-4-[(carboxycarbonyl)(2-carboxyphenyl)amino]-3-(2-hydroxyethyl)phenylalanyl)amino]pentanoyl}-L-methionine.

25. The compound according to claim 2, wherein

L is



R_8 is NR_AR_B ;

R_{9A} and R_{9B} together are oxo;


X_2 is NR_C ;

X_3 is S; and

B is aryl.

26. The compound according to claim 2, wherein

L is



R_8 is NR_AR_B ;

R_{9A} and R_{9B} together are oxo;

X_2 is NR_C ;

X_3 is S;

B is aryl; and

A is




27. The compound according to claim 26, which is

N-{5-[(*N*-acetyl-4-[(carboxycarbonyl)(2-carboxyphenyl)amino]-3-ethylphenylalanyl)amino]pentanoyl}-*S*-benzyl-L-cysteine.

28. The compound according to claim 2, wherein

L is



R_8 is NR_AR_B ;


R_{9A} and R_{9B} together are oxo;

X_2 is NR_C ;

X_3 is S;

B is alkyl; and

A is



29. The compound according to claim 28, which is
 N -(5-{[3-(4-[(carboxycarbonyl)(2-carboxyphenyl)amino]-1-naphthyl)- N -(methoxycarbonyl)alanyl]amino}pentanoyl)- L -methionine.

30. The compound according to claim 2, wherein
 L is $-(CH_2)_mX_1(CH_2)_nCH(R_8)C(R_{9A})(R_{9B})X_2(CH_2)_pX_3-$.

31. The compound according to claim 2, wherein
 L is $-(CH_2)_mX_1(CH_2)_nCH(R_8)C(R_{9A})(R_{9B})X_2(CH_2)_pX_3-$; and
 R_8 is NR_AR_B .

32. The compound according to claim 2, wherein
 L is $-(CH_2)_mX_1(CH_2)_nCH(R_8)C(R_{9A})(R_{9B})X_2(CH_2)_pX_3-$;
 R_8 is NR_AR_B ; and
 R_{9A} and R_{9B} together are oxo.

33. The compound according to claim 2, wherein
 L is $-(CH_2)_mX_1(CH_2)_nCH(R_8)C(R_{9A})(R_{9B})X_2(CH_2)_pX_3-$;
 R_8 is NR_AR_B ;
 R_{9A} and R_{9B} together are oxo; and
 X_2 is NR_C .

34. The compound according to claim 2, wherein
 L is $-(CH_2)_mX_1(CH_2)_nCH(R_8)C(R_{9A})(R_{9B})X_2(CH_2)_pX_3-$;
 R_8 is NR_AR_B ;
 R_{9A} and R_{9B} together are oxo;
 X_2 is NR_C ; and
 X_3 is O.

35. The compound according to claim 2, wherein
 L is $-(CH_2)_mX_1(CH_2)_nCH(R_8)C(R_{9A})(R_{9B})X_2(CH_2)_pX_3-$;
 R_8 is NR_AR_B ;

R_{9A} and R_{9B} together are oxo;

X_2 is NR_C ;

X_3 is O; and

B is aryl.

36. The compound according to claim 2, wherein

L is $-(CH_2)_mX_1(CH_2)_nCH(R_8)C(R_{9A})(R_{9B})X_2(CH_2)_pX_3-$;

R_8 is NR_AR_B ;

R_{9A} and R_{9B} together are oxo;

X_2 is NR_C ;

X_3 is O;

B is aryl; and

A is



37. The compound according to claim 36, selected from the group consisting of
methyl 2-[4-({*N*-[(allyloxy)carbonyl]-4-[(carboxycarbonyl)(2-carboxyphenyl)amino]-
L-phenylalanyl] amino)butoxy]-6-hydroxybenzoate;

methyl 2-[4-({*N*-acetyl-4-[(carboxycarbonyl)(2-carboxyphenyl)amino]-3-
ethylphenylalanyl] amino)butoxy]-6-hydroxybenzoate;

methyl 4-[4-({*N*-acetyl-4-amino-3-ethylphenylalanyl] amino)butoxy]-2-hydroxy-1,1'-
biphenyl-3-carboxylate;

2-[4-({*N*-acetyl-4-[(carboxycarbonyl)(2-carboxyphenyl)amino]-3-
ethylphenylalanyl] amino)butoxy]-6-hydroxybenzoic acid;

methyl 6-[4-({*N*-acetyl-4-[(carboxycarbonyl)(2-carboxyphenyl)amino]-3-
ethylphenylalanyl] amino)butoxy]-3-bromo-2-hydroxybenzoate;

methyl 2-[4-({[4-[(carboxycarbonyl)(2-carboxyphenyl)amino]-*N*-(methoxycarbonyl)-
L-phenylalanyl] amino} butoxy)-6-hydroxy-4-pentylbenzoate;

methyl 2-[4-({[4-[(carboxycarbonyl)(2-carboxyphenyl)amino]-*N*-(methoxycarbonyl)-
L-phenylalanyl] amino} butoxy)-6-hydroxy-4-methoxybenzoate;

methyl 3-[4-({[4-[(carboxycarbonyl)(2-carboxyphenyl)amino]-*N*-(methoxycarbonyl)-
L-phenylalanyl] amino} butoxy)-5-hydroxy-1,1'-biphenyl-4-carboxylate;

methyl 2-[4-({[4-[(carboxycarbonyl)(2-carboxyphenyl)amino]-*N*-(methoxycarbonyl)-
L-phenylalanyl] amino} butoxy)-6-hydroxy-4-methylbenzoate;

methyl 2-(4-{[4-[(carboxycarbonyl)(2-carboxyphenyl)amino]-*N*-(methoxycarbonyl)-*L*-phenylalanyl]amino}butoxy)-4-chloro-6-hydroxybenzoate;

methyl 2-(4-{[4-[(carboxycarbonyl)(2-carboxyphenyl)amino]-*N*-(methoxycarbonyl)-*L*-phenylalanyl]amino}butoxy)-6-hydroxybenzoate;

4-[(carboxycarbonyl)(2-carboxyphenyl)amino]-*N*-(4-[2-(aminocarbonyl)-3-hydroxyphenoxy]butyl)-*N*-(methoxycarbonyl)-*L*-phenylalaninamide;

methyl 3-(4-{[4-[(carboxycarbonyl)(2-carboxyphenyl)amino]-*N*-(methoxycarbonyl)-*L*-phenylalanyl]amino}butoxy)-1-hydroxy-2-naphthoate;

4-[(carboxycarbonyl)(2-carboxyphenyl)amino]-*N*-(4-{3-hydroxy-2-[(methylamino)carbonyl]phenoxy}butyl)-*N*-(methoxycarbonyl)-*L*-phenylalaninamide;

4-[(carboxycarbonyl)(2-carboxyphenyl)amino]-*N*-(4-{2-[(ethylamino)carbonyl]-3-hydroxyphenoxy}butyl)-*N*-(methoxycarbonyl)-*L*-phenylalaninamide;

N-(4-[2-(acetylamino)-3-hydroxyphenoxy]butyl)-4-[(carboxycarbonyl)(2-carboxyphenyl)amino]-*N*-(methoxycarbonyl)-*L*-phenylalaninamide; and

4-[(carboxycarbonyl)(2-carboxyphenyl)amino]-*N*-(4-{2-[(dimethylamino)carbonyl]-3-hydroxyphenoxy}butyl)-*N*-(methoxycarbonyl)-*L*-phenylalaninamide.

38. The compound according to claim 2, wherein

L is $-(\text{CH}_2)_m\text{X}_1(\text{CH}_2)_n\text{CH}(\text{R}_8)\text{C}(\text{R}_{9A})(\text{R}_{9B})\text{X}_2(\text{CH}_2)_p\text{X}_3$;

R_8 is NR_AR_B ;


R_{9A} and R_{9B} together are oxo;

X_2 is NR_C ;

X_3 is O;

B is aryl; and

A is



39. The compound according to claim 38, selected from the group consisting of

methyl 2-[(5-{[*N*-acetyl-3-(4-amino-1-naphthyl)-*L*-alanyl]amino}pentyl)oxy]-6-hydroxy-4-methylbenzoate; and

3-[(5-{[*N*-acetyl-3-{4-[(carboxycarbonyl)(2-carboxyphenyl)amino]-1-naphthyl}-*L*-alanyl]amino}pentyl)oxy)-2-naphthoic acid.

40. The compound according to claim 2, wherein

L is $-(\text{CH}_2)_m\text{X}_1(\text{CH}_2)_n\text{CH}(\text{R}_8)\text{C}(\text{R}_{9A})(\text{R}_{9B})\text{X}_2(\text{CH}_2)_p\text{X}_3-$; and
 R_8 is hydrogen.

41. The compound according to claim 2, wherein

5 L is $-(\text{CH}_2)_m\text{X}_1(\text{CH}_2)_n\text{CH}(\text{R}_8)\text{C}(\text{R}_{9A})(\text{R}_{9B})\text{X}_2(\text{CH}_2)_p\text{X}_3-$;
 R_8 is hydrogen; and
 R_{9A} and R_{9B} together are oxo.

42. The compound according to claim 2, wherein

10 L is $-(\text{CH}_2)_m\text{X}_1(\text{CH}_2)_n\text{CH}(\text{R}_8)\text{C}(\text{R}_{9A})(\text{R}_{9B})\text{X}_2(\text{CH}_2)_p\text{X}_3-$;
 R_8 is hydrogen;
 R_{9A} and R_{9B} together are oxo; and
 X_2 is NR_C .

43. The compound according to claim 2, wherein

15 L is $-(\text{CH}_2)_m\text{X}_1(\text{CH}_2)_n\text{CH}(\text{R}_8)\text{C}(\text{R}_{9A})(\text{R}_{9B})\text{X}_2(\text{CH}_2)_p\text{X}_3-$;
 R_8 is hydrogen;
 R_{9A} and R_{9B} together are oxo;
 X_2 is NR_C ; and
 X_3 is O.

44. The compound according to claim 2, wherein

20 L is $-(\text{CH}_2)_m\text{X}_1(\text{CH}_2)_n\text{CH}(\text{R}_8)\text{C}(\text{R}_{9A})(\text{R}_{9B})\text{X}_2(\text{CH}_2)_p\text{X}_3-$;
 R_8 is hydrogen;
 R_{9A} and R_{9B} together are oxo;
 X_2 is NR_C ;
 X_3 is O; and
B is aryl.


45. The compound according to claim 2, wherein

30 L is $-(\text{CH}_2)_m\text{X}_1(\text{CH}_2)_n\text{CH}(\text{R}_8)\text{C}(\text{R}_{9A})(\text{R}_{9B})\text{X}_2(\text{CH}_2)_p\text{X}_3-$;
 R_8 is hydrogen;
 R_{9A} and R_{9B} together are oxo;
 X_2 is NR_C ;
 X_3 is O; and
B is aryl; and
A is



46. The compound according to claim 45, which is methyl 2-(4-{[3-(4-[(carboxycarbonyl)(2-carboxyphenyl)amino]-3-ethylphenyl)propanoyl]amino}butoxy)-6-hydroxybenzoate.

47. The compound according to claim 2, wherein
 L is $-(CH_2)_mX_1(CH_2)_nCH(R_8)C(R_{9A})(R_{9B})X_2(CH_2)_pX_3-$;
 R_8 is hydrogen;
 R_{9A} and R_{9B} together are oxo;
 X_2 is NR_C ;
 X_3 is O;
 B is aryl; and
 A is



48. The compound according to claim 47, which is 2-((carboxycarbonyl){4-[3-(4-[3-hydroxy-2-(methoxycarbonyl)phenoxy]butyl)amino]-3-oxopropyl]}[(carboxycarbonyl)(2-carboxyphenyl)amino]-1-naphthyl)amino)benzoic acid.


49. The compound according to claim 2, wherein
 L is $-(CH_2)_mX_1(CH_2)_nCH(R_8)C(R_{9A})(R_{9B})X_2(CH_2)_pX_3-$;
 R_8 is hydrogen; and
 R_{9A} is alkyl.

50. The compound according to claim 2, wherein
 L is $-(CH_2)_mX_1(CH_2)_nCH(R_8)C(R_{9A})(R_{9B})X_2(CH_2)_pX_3-$;
 R_8 is hydrogen;
 R_{9A} is alkyl; and
 X_2 is NR_C .

51. The compound according to claim 2, wherein
 L is $-(CH_2)_mX_1(CH_2)_nCH(R_8)C(R_{9A})(R_{9B})X_2(CH_2)_pX_3-$;
 R_8 is hydrogen;
 R_{9A} is alkyl;
 X_2 is NR_C ; and
 X_3 is O.

52. The compound according to claim 2, wherein
 L is $-(CH_2)_mX_1(CH_2)_nCH(R_8)C(R_{9A})(R_{9B})X_2(CH_2)_pX_3-$;
 R_8 is hydrogen;
 R_{9A} is alkyl;
 X_2 is NR_C ;
 X_3 is O; and
 B is aryl.

53. The compound according to claim 2, wherein
 L is $-(CH_2)_mX_1(CH_2)_nCH(R_8)C(R_{9A})(R_{9B})X_2(CH_2)_pX_3-$;
 R_8 is hydrogen;
 R_{9A} is alkyl;
 X_2 is NR_C ;
 X_3 is O;
 B is aryl; and
 A is



54. The compound according to claim 53, which is
 methyl 2-(4-[[3-(4-[(carboxycarbonyl)(2-carboxyphenyl)amino]-1-naphthyl)-1-methylpropyl]amino]butoxy)-6-hydroxybenzoate.


55. The compound according to claim 2, wherein
 L is $-(CH_2)_mX_1(CH_2)_nCH(R_8)C(R_{9A})(R_{9B})X_2(CH_2)_pX_3-$;
 R_8 is hydrogen; and
 R_{9A} and R_{9B} are both hydrogen.

56. The compound according to claim 2, wherein
 L is $-(CH_2)_mX_1(CH_2)_nCH(R_8)C(R_{9A})(R_{9B})X_2(CH_2)_pX_3-$;
 R_8 is hydrogen;
 R_{9A} and R_{9B} are both hydrogen; and
 X_2 is NR_C .

57. The compound according to claim 2, wherein
 L is $-(CH_2)_mX_1(CH_2)_nCH(R_8)C(R_{9A})(R_{9B})X_2(CH_2)_pX_3-$;
 R_8 is hydrogen;
 R_{9A} and R_{9B} are both hydrogen;
 X_2 is NR_C ; and
 X_3 is O.

58. The compound according to claim 2, wherein
 L is $-(CH_2)_mX_1(CH_2)_nCH(R_8)C(R_{9A})(R_{9B})X_2(CH_2)_pX_3-$;
 R_8 is hydrogen;
 R_{9A} and R_{9B} are both hydrogen;
 X_2 is NR_C ;
 X_3 is O; and
 B is aryl.

59. The compound according to claim 2, wherein
 L is $-(CH_2)_mX_1(CH_2)_nCH(R_8)C(R_{9A})(R_{9B})X_2(CH_2)_pX_3-$;
 R_8 is hydrogen;
 R_{9A} and R_{9B} are both hydrogen;
 X_2 is NR_C ;
 X_3 is O;
 B is aryl; and
 A is



60. The compound according to claim 59, which is
 methyl 2-(4-[[3-(4-[(carboxycarbonyl)(2-carboxyphenyl)amino]-1-naphthyl)propyl]amino]butoxy)-6-hydroxybenzoate.

61. The compound according to claim 2, wherein
 L is $-(CH_2)_mX_1(CH_2)_nCH(R_8)C(R_{9A})(R_{9B})X_2(CH_2)_pX_3(CH_2)_qX_4-$.
- 5 62. The compound according to claim 2, wherein
 L is $-(CH_2)_mX_1(CH_2)_nCH(R_8)C(R_{9A})(R_{9B})X_2(CH_2)_pX_3(CH_2)_qX_4-$; and
 R_8 is NR_AR_B .
- 10 63. The compound according to claim 2, wherein
 L is $-(CH_2)_mX_1(CH_2)_nCH(R_8)C(R_{9A})(R_{9B})X_2(CH_2)_pX_3(CH_2)_qX_4-$;
 R_8 is NR_AR_B ; and
 R_{9A} and R_{9B} together are oxo.
- 15 64. The compound according to claim 2, wherein
 L is $-(CH_2)_mX_1(CH_2)_nCH(R_8)C(R_{9A})(R_{9B})X_2(CH_2)_pX_3(CH_2)_qX_4-$;
 R_8 is NR_AR_B ;
 R_{9A} and R_{9B} together are oxo; and
 X_2 is NR_C .
- 20 65. The compound according to claim 2, wherein
 L is $-(CH_2)_mX_1(CH_2)_nCH(R_8)C(R_{9A})(R_{9B})X_2(CH_2)_pX_3(CH_2)_qX_4-$;
 R_8 is NR_AR_B ;
 R_{9A} and R_{9B} together are oxo;
 X_2 is NR_C ; and
 X_3 is O.
- 25 66. The compound according to claim 2, wherein
 L is $-(CH_2)_mX_1(CH_2)_nCH(R_8)C(R_{9A})(R_{9B})X_2(CH_2)_pX_3(CH_2)_qX_4-$;
 R_8 is NR_AR_B ;
 R_{9A} and R_{9B} together are oxo;
 X_2 is NR_C ;
 X_3 is O; and
 X_4 is O.
- 30 67. The compound according to claim 2, wherein
 L is $-(CH_2)_mX_1(CH_2)_nCH(R_8)C(R_{9A})(R_{9B})X_2(CH_2)_pX_3(CH_2)_qX_4-$;
 R_8 is NR_AR_B ;
- 35

R_{9A} and R_{9B} together are oxo;

X_2 is NR_C ;

X_3 is O;

X_4 is O; and

B is aryl.

68. The compound according to claim 2, wherein

L is $-(CH_2)_mX_1(CH_2)_nCH(R_8)C(R_{9A})(R_{9B})X_2(CH_2)_pX_3(CH_2)_qX_4-$;

R_8 is NR_AR_B ;

R_{9A} and R_{9B} together are oxo;

X_2 is NR_C ;

X_3 is O;

X_4 is O;

B is aryl; and

A is



69. The compound according to claim 68, which is

methyl 2-{2-[2-({*N*-[(allyloxy)carbonyl]-4-[(carboxycarbonyl)(2-carboxyphenyl)amino]-L-phenylalanyl}amino)ethoxy]ethoxy}-6-hydroxybenzoate;

70. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 in combination with a pharmaceutically acceptable carrier.

71. A method of method of selectively inhibiting protein tyrosine phosphatase 1B comprising administering a therapeutically effective amount of a compound of claim 1.

72. A method of treating disorders caused by overexpressed or altered protein tyrosine phosphatase 1B comprising administering a therapeutically effective amount of a compound of claim 1.

73. The method of claim 72, wherein the disorder is type I and type II diabetes.

74. The method of claim 72, wherein the disorder is obesity.

75. A method of claim 72, wherein the disorder is autoimmune disorders, acute and chronic inflammatory disorders, osteoporosis, cancer, malignant disorders.

00280-7277660